AutoGenomics Receives FDA Clearance for its INFINTI™ Warfarin Assay
Carlsbad, CA, January 24, 2008 - AutoGenomics, a leader in developing automated molecular testing solutions announced today that it has obtained clearance from the Food and Drug Administration (FDA) for its INFINITI 2C9-VKORC1 Multiplex Assay for Warfarin. The company has already received FDA clearance for its INFINITI Analyzer and Factor II/Factor V Leiden Leiden assays in 2007.
"We are excited to receive FDA clearance for our warfarin test" said Fareed Kureshy, President and CEO of AutoGenomics. "The FDA recently re-labeled warfarin stating that genetic testing may help optimize the use of the drug and lower the risk of bleeding complications. Several of our customers are awaiting such clearance to implement testing in their practice. We continue to expand our product portfolio with additional warfarin assays and are committed to be the lead player in this testing arena"
AutoGenomics Inc., a privately held company based in Carlsbad, CA, has developed the first automated, microarray based multiplexing diagnostic platforms that can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics. With the discovery of genes and their link to various disease states the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed leading to the era of personalized medicine. For more information, please visit www.autogenomics.com
For further information please contact:
Senior Vice President Sales & Marketing, AutoGenomics
760-804-7378 x 305